Chymase Inhibitors

Author(s): Eiji Yahiro, Shin-ichiro Miura, Satoshi Imaizumi, Yoshinari Uehara, Keijiro Saku

Journal Name: Current Pharmaceutical Design

Volume 19 , Issue 17 , 2013

Become EABM
Become Reviewer
Call for Editor


Chymase, a chymotrypsin-like serine protease that is abundant in secretory granules from mast cells, has been identified to be a key enzyme in the local renin-angiotensin system (RAS) that generates angiotensin II (Ang II) independent of angiotensin converting enzyme (ACE). The pathophysiological significance of alternative Ang II-forming pathways in human cardiovascular disease remains controversial. Although chymase inhibitors, unlike ACE inhibitors and Ang II type 1 receptor blockers (ARBs), may only play a small role in the regulation of the systemic RAS, the possible applications of chymase inhibitors as new drugs that inhibit the local RAS to prevent cardiovascular diseases are described in animal models. In this review, we discuss the possible application of chymase inhibitors as new drugs to inhibit the RAS in mainly cardiovascular diseases.

Keywords: Local renin-angiotensin system, angiotensin II-forming pathways, angiotensin converting enzyme inhibitor, angiotensin II type 1 receptor blockers.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 01 April, 2013
Page: [3065 - 3071]
Pages: 7
DOI: 10.2174/1381612811319170014
Price: $65

Article Metrics

PDF: 56